Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

Blood Cancer J. 2024 Sep 5;14(1):152. doi: 10.1038/s41408-024-01134-3.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Dexamethasone* / administration & dosage
  • Dexamethasone* / therapeutic use
  • Drug Resistance, Neoplasm / drug effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma* / drug therapy
  • Thalidomide* / administration & dosage
  • Thalidomide* / analogs & derivatives
  • Thalidomide* / therapeutic use

Substances

  • pomalidomide
  • Antibodies, Monoclonal, Humanized
  • Dexamethasone
  • elotuzumab
  • daratumumab
  • Thalidomide
  • Antibodies, Monoclonal